LEADER 01360nam  2200385   450 
001 9910706904703321
005 20180503134057.0
035   $a(CKB)5470000002460435
035   $a(OCoLC)1033691730
035   $a(EXLCZ)995470000002460435
100   $a20180503d2018      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFood and Drug Administration: information on Mifeprex labeling changes and ongoing monitoring efforts $ereport to congressional requesters
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2018.
215   $a1 online resource (ii, 29 pages)
300   $a"March 2018."
300   $a"GAO-18-292."
320   $aIncludes bibliographical references.
517   $aFood and Drug Administration
606   $aMifepristone$zUnited States$xTesting
606   $aDrugs$xLabeling$xStandards$zUnited States
606   $aDrugs$zUnited States$xTesting
615  0$aMifepristone$xTesting.
615  0$aDrugs$xLabeling$xStandards
615  0$aDrugs$xTesting.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910706904703321
996   $aFood and Drug Administration: information on Mifeprex labeling changes and ongoing monitoring efforts$93447019
997   $aUNINA